Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

October 20, 2020

Conditions

Healthy

Interventions

DRUG

Sphingomod

1 capsule contains 0.5 mg Fingolimod

DRUG

Gilenya

1 capsule contains 0.5 mg Fingolimod

Trial Locations (1)

Genuine Research Center GRC, Cairo